Nexalin Technology, Inc. (NASDAQ: NXL) announced the launch of its AI‑designed NeuroCare® virtual clinic platform, integrated with the company’s Gen‑3 HALO headset, in partnership with the University of California, San Diego. The platform delivers deep intracranial frequency stimulation (DIFS) to patients with Alzheimer’s disease, mood disorders, traumatic brain injury, and PTSD, and is designed to operate under remote physician supervision in a subscription‑based home‑care model.
The Gen‑3 HALO headset is a home‑based neurostimulation device that delivers DIFS directly to the brain. By combining the headset with an AI‑driven virtual clinic, Nexalin aims to reduce stigma, lower costs, and increase patient access to brain‑health treatment. The subscription model is intended to create recurring revenue and long‑term patient engagement, a strategic pivot from the company’s earlier device‑sales focus.
Nexalin’s recent financial performance underscores the urgency of this launch. In Q3 2025 the company generated $18,149 in revenue, a 50% decline from $36,031 in Q3 2024, and posted a net loss of $2,276,311. The loss reflects heavy investment in research and development, clinical trials, and the commercialization of the HALO platform, as well as limited sales volume in the early‑stage product cycle. The company’s cash reserves of $590,075 and short‑term investments of $3,762,602 highlight the need for a scalable, recurring revenue stream to support future growth.
The market reacted positively to the announcement. Early trading saw the stock rise 6.7%, and pre‑market activity pushed the price up 11.51%. Investors were driven by the strategic shift to a digital‑health ecosystem, the credibility added by the UCSD partnership, and the potential for a recurring revenue model that could offset the company’s current losses and accelerate profitability.
Regulatory approval remains a key headwind. The Gen‑3 HALO headset is still awaiting FDA clearance, and the success of the clinical trials at UCSD will be critical for broader adoption. Competition in the neurotechnology and digital‑health space is intense, and the company’s limited cash position could constrain its ability to scale quickly. Nonetheless, the launch positions Nexalin to capture a growing market for remote, non‑invasive brain‑health solutions and to build a data‑driven platform that could drive future revenue growth.
CEO Mark White emphasized the strategic importance of the launch: “Today we begin a new chapter in how brain‑health therapy is delivered. By launching our Gen‑3 HALO neurostimulation system with the NeuroCare AI‑designed virtual clinic platform, in partnership with UCSD, we remove the mental health stigma, eliminate access barriers to treatment, and lower the cost for patients and physicians alike. Nexalin is committed to building a foundation for a long‑term relationship with its clients with recurring monthly subscriptions, long‑term treatment adherence, and data‑driven outcomes across Alzheimer’s, mood disorders, and active military and veteran‑care applications.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.